Hypothesis: Thalidomide embryopathy - Proposed mechanism of action

Teratology

Volumn 61, Issue 3, 2000, Pages 189-195

  Stephens, Trent D ^a   Fillmore, Bradley J ^a  

^a Nucl Eng Idaho State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CYTOSINE; FIBROBLAST GROWTH FACTOR 1; GUANINE; INTEGRIN; PROTEIN; SOMATOMEDIN C; THALIDOMIDE; TRANSCRIPTION FACTOR SP1;

ANGIOGENESIS; ARTICLE; EMBRYOPATHY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HYDROLYSIS; LIMB BUD; LIMB DEVELOPMENT; MESENCHYME CELL; METABOLISM; PRIORITY JOURNAL; PROMOTER REGION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MATERNAL-FETAL EXCHANGE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; TERATOGENS; THALIDOMIDE;

EID: 0034058818     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W     Document Type: Article

References (41)

1. Araki E, Haag BL, Matsuda K, Shichiri M, Kahn CR. 1995. Characterization and regulation of the mouse insulin receptor substrate gene promoter. Mol Endocrinol 9:1367-1379.
2. Argiles JM, Carbo N, Lopez-Soriano FJ. 1998. Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 50:313-318.
3. Ashby J, Tinwell H, Callander RD, Kimber I, Clay P, Galloway SM, Hill RB, Greenwood SK, Gaulden ME, Ferguson MJ, Vogel E, Nivard M, Parry JM, Williamson J. 1997. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat Res 396:45-64.
4. Battegay EJ. 1995. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333-346.
5. Bauer KS, Dixon SC, Figg WD. 1998. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834.
6. Benito M, Valverde AM, Lorenzo M. 1996. IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Int J Biochem Cell Biol 28:499-510.
7. Block KL, Shou Y, Poncz M. 1996. An Ets/Sp1 interaction in the 5′-flanking region of the megakaryocyte-specific alpha IIb gene appears to stabilize Sp1 binding and is essential for expression of this TATA-less gene. Blood 88:2071-2080.
8. Boisclair YR, Brown AL, Casola S, Rechler MM. 1993. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem 268:24892-24901.
9. Brooks PC, Clark RA, Cheresh DA. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571.
10. Bucher P. 1990. Weight matrix descriptions of four eukaryotic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J Mol Biol 212:563-578.
11. Cao X, Ross FP, Zhang L, MacDonald PN, Chappel J, Teitelbaum SL. 1993. Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J Biol Chem 268:27371-27380.
12. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K. 1997. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 272:25176-83.
13. Cooke DW, Bankert LA, Roberts, Jr CT, LeRoith D, Casella SJ. 1991. Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun 177:1113-1120.
14. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc NatlAcad Sci USA 91:4082-4085.
15. Dealy CN, Kosher RA. 1996. IGF-I, insulin and FGFs induce outgrowth of the limb buds of amelic mutant chick embryos. Development 122:1323-1330.
16. Donahue JP, Sugg N, Hawiger J. 1994. The integrin alpha v gene: identification and characterization of the promoter region. Biochim Biophys Acta 1219:228-232.
17. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
18. Geduspan JS, Solursh M. 1993. Effects of the mesonephros and insulin-like growth factor-I on chondrogenesis of limb explants. Devl Biol 156:500-508.
19. Green BN, Jones SB, Streck RD, Wood TL, Rotwein P, Pintar JE. 1994. Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during fetal and postnatal development. Endocrinology 134:954-962.
20. Jones JI, Prevette T, Gockerman A, Clemmons DR. 1996. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 93:2482-2487.
21. Jönsson NA. 1972. Chemical structure and teratogenic properties IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm Suecica 9:543-562.
22. Kenyon BM, Browne F, D'Amato RJ. 1997. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978.
23. Koch HP, Czejka MJ. 1986. Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity? Z Naturforsch [C] 41:1057-1061.
24. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. 1998. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461-466.
25. Lamb KA, Johnson LR, Rizzino A. 1997. NF-Y binds to the CCAAT box motif of the FGF-4 gene and promotes FGF-4 expression in embryonal carcinoma cells. Mol Reprod Dev 48:301-309.
26. Madiai F, Hackshaw KV, Chiu IM. 1999. Characterization of the entire transcription unit of the mouse fibroblast growth factor 1 (FGF-1) gene. Tissue-specific expression of the FGF-1.A mRNA. J Biol Chem 274:11937-11944.
27. Meise W, Ockenfels H, Köhler F. 1973. Teratologische prüfung der hydrolysenprodukte des thalidomids. Experientia 29:423-424.
28. Myers MG Jr, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, White MF. 1994. Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269: 28783-28789.
29. Neubert R, Hinz N, Thiel R, Neubert D. 1996. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58:295-316.
30. Newberry EP, Willis D, Latifi T, Boudreaux JM, Towler DA. 1997. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element. Mol Endocrinol 11:1129-1144.
31. Pardanaud L, Yassine F, Dieterlen-Lievre F. 1989. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 105:473-85.
32. Pasumarthi KB, Jin Y, Cattini PA. 1997. Cloning of the rat fibroblast growth factor-2 promoter region and its response to mitogenic stimuli in glioma C6 cells. J Neurochem 68:898-908.
33. Perez-Castro AV, Wilson J, Altherr MR. 1997. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 41:10-16.
34. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP. 1997. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619-26.
35. Quibell EP. 1981. The thalidomide embryopathy. An analysis from the UK. Practitioner 225:721-726.
36. Scrimgeour AG, Blakesley VA, Stannard BS, LeRoith D. 1997. Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 138:2552-2558.
37. Stephens TD. 1988. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38:229-239.
38. Stephens TD, Bunde CJW, Torres RD, Hackett DA, Stark MR, Smith DM, Fillmore BJ. 1998. Thalidomide inhibits limb development through its antagonism of IFG-I + FGF-2 + Heparin. Teratology 57:112[abs].
39. Tabin CJ. 1998. A developmental model for thalidomide defects. Nature 396:322-323.
40. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM. 1997. Oxidative damage in chemical teratogenesis. Mutat Res 396:65-78.
41. Werner H, Stannard B, Bach MA, LeRoith D, Roberts Jr CT. 1990. Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun 169:1021-1027.